Literature DB >> 7811030

Antimicrobial susceptibility of pathogenic Yersinia enterocolitica isolated in Canada from 1972 to 1990.

M A Preston1, S Brown, A A Borczyk, G Riley, C Krishnan.   

Abstract

Yersinia enterocolitica has emerged as an enteropathogen associated with several types of human infections that often require antimicrobial therapy, but little is known about the antimicrobial susceptibilities of pathogenic strains isolated from humans in Canada. To determine the present patterns of antimicrobial susceptibility, to identify changes in these patterns that occurred during the past two decades, and to investigate the relationships between O serotypes and patterns of susceptibility, we tested a total of 1,105 pathogenic Y. enterocolitica strains isolated during 1972 to 1976, 1980, 1985, and 1990 for their susceptibilities to 22 antimicrobial agents. Susceptibility testing was performed by using a single breakpoint concentration in agar procedure. The results showed that all strains were susceptible to ciprofloxacin and piperacillin, and 98% or more of the strains from each period were susceptible to trimethoprim, sulfamethoxazole, cotrimoxazole, tetracycline, chloramphenicol, cefamandole, cefotaxime, aztreonam, and four aminoglycosides. In contrast, all strains were nonsusceptible to erythromycin, furazolidone, and clindamycin and 90% or more of the strains from each period were nonsusceptible to ampicillin, carbenicillin, ticarcillin, and cephalothin. Strains belonging to serotypes O:3, O:5,27, and O:8 had different patterns of susceptibility to ampicillin, carbenicillin, ticarcillin, and amoxicillin-clavulanic acid. No major difference in susceptibility was observed between any of the groups of human or animal strains included in the study, but nonsusceptibility to tetracycline increased from 0.4% in 1985 to 2% in 1990 in human strains isolated in those years. Our results indicate that between 1972 and 1990 there was no marked decrease in susceptibility to agents commonly used for therapy among pathogenic Y. enterocolitica strains isolated in Canada.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7811030      PMCID: PMC284695          DOI: 10.1128/AAC.38.9.2121

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  Transfusing Yersinia enterocolitica.

Authors:  M Prentice
Journal:  BMJ       Date:  1992-09-19

2.  Drug susceptibility of Yersinia enterocolitica and Yersinia pseudotuberculosis.

Authors:  Y Kanazawa; K Ikemura; T Kuramata
Journal:  Contrib Microbiol Immunol       Date:  1987

3.  Antibiotics in Yersinia enterocolitica infections.

Authors:  J A Hoogkamp-Korstanje
Journal:  J Antimicrob Chemother       Date:  1987-07       Impact factor: 5.790

4.  Antimicrobial susceptibilities of Yersinia enterocolitica biotype 4, serotype O:3.

Authors:  S Hammerberg; S Sorger; M I Marks
Journal:  Antimicrob Agents Chemother       Date:  1977-03       Impact factor: 5.191

5.  Placebo-controlled double-blind evaluation of trimethoprim-sulfamethoxazole treatment of Yersinia enterocolitica gastroenteritis.

Authors:  C H Pai; F Gillis; E Tuomanen; M I Marks
Journal:  J Pediatr       Date:  1984-02       Impact factor: 4.406

6.  Yersinia enterocolitica: in vitro antimicrobial susceptibility.

Authors:  M Raevuori; S M Harvey; M J Pickett; W J Martin
Journal:  Antimicrob Agents Chemother       Date:  1978-05       Impact factor: 5.191

7.  Antimicrobial susceptibilities of food-isolated strains of Yersinia enterocolitica, Y. intermedia, Y. frederiksenii, and Y. kristensenii.

Authors:  A Ahmedy; D J Vidon; C L Delmas; M C Lett
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

8.  Comparative in vitro activities of ten antimicrobial agents against bacterial enteropathogens.

Authors:  J R Carlson; S A Thornton; H L DuPont; A H West; J J Mathewson
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

9.  Survey on the incidence of Yersinia enterocolitica infection in Canada.

Authors:  S Toma; L Lafleur
Journal:  Appl Microbiol       Date:  1974-09

10.  In vitro susceptibilities of 126 clinical isolates of Yersinia enterocolitica to 21 beta-lactam antibiotics.

Authors:  M J Hornstein; A M Jupeau; M R Scavizzi; A M Philippon; P A Grimont
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

View more
  4 in total

1.  An outbreak of Yersinia enterocolitica in a captive colony of African green monkeys (Chlorocebus aethiops sabaeus) in the Caribbean.

Authors:  Esteban Soto; Matt Griffin; Ashutosh Verma; Fernanda Castillo-Alcala; Amy Beierschmitt; Janet Beeler-Marfisi; Maziel Arauz; Oscar Illanes
Journal:  Comp Med       Date:  2013-10       Impact factor: 0.982

2.  Bacterial pathogens associated with diarrhoea on the island of Crete.

Authors:  G Samonis; S Maraki; A Christidou; A Georgiladakis; Y Tselentis
Journal:  Eur J Epidemiol       Date:  1997-10       Impact factor: 8.082

3.  Bacterial colitis.

Authors:  Harry T Papaconstantinou; J Scott Thomas
Journal:  Clin Colon Rectal Surg       Date:  2007-02

Review 4.  Drug Resistance and the Prevention Strategies in Food Borne Bacteria: An Update Review.

Authors:  Fataneh Hashempour-Baltork; Hedayat Hosseini; Saeedeh Shojaee-Aliabadi; Mohammadali Torbati; Adel Mirza Alizadeh; Matin Alizadeh
Journal:  Adv Pharm Bull       Date:  2019-08-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.